An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of ES002023 in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 21 Oct 2022
At a glance
- Drugs ES 002 (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Elpiscience Biopharmaceuticals
- 18 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 20 Jan 2022 According to an Elpiscience Biopharmaceuticals media release, the first patient has been dosed in the study.
- 20 Jan 2022 Status changed from not yet recruiting to recruiting, according to an Elpiscience Biopharmaceuticals media release.